Special Issue Title:

The Management of Breast Cancer

Deadline for manuscript submissions: 01 September 2023

Print Special Issue Flyer (12)

Special Issue Editor

  • Guest Editor

    Yutian Zou, MDE-MailWebsite

    Department of Breast Oncology, Sun Yat-sen University Cancer Center, China

    Interests: Breast Cancer; Surgery; Immunotherapy; Drug Resistance; Molecular Biology

Special Issue Information

Dear Colleagues,

Breast cancer has become the most pervasive malignancy that seriously affects women's survival worldwide. Breast cancer is acknowledged as a heterogeneous disease with four major different molecular subtypes (luminal A, luminal B, HER2-enriched, and basal-like). More than 90% of breast cancers are not metastatic at the time of diagnosis. For people presenting without metastatic disease, therapeutic goals are tumor eradication and preventing recurrence. However, surgery is rarely used as monotherapy, and most patients will expect concurrent chemotherapy, radiotherapy, hormonal treatment, or pharmacotherapy with cancer-targeting drug molecules. Knowing which treatment courses to use for each patient case can be challenging. Identifying markers and diagnostics to guide these decisions is pivotal in refining the breast cancer treatment cascade. Despite the progress and advancements in the systematic treatment of breast cancer, some patients will still experience distant metastatic disease in the first five years. Patients with advanced breast cancer have a poor prognosis. In recent years, a series of new drugs have been developed and proven effective for advanced breast cancer. CDK4/6 kinase inhibitors were approved for use in combination with endocrine therapy, which significantly increase the progression-free survival of patients with advanced estrogen receptor-positive breast cancer in the first-line treatment setting. Trastuzumab deruxtecan (DS-8201), an antibody-drug conjugate composed of an anti-HER2 antibody and a cytotoxic topoisomerase I inhibitor, was approved by the US Food and Drug Administration for the treatment of unresectable or metastatic HER2-positive breast cancer. Additionally, immune checkpoint therapy has been proved as an effective strategy in advanced triple-negative breast cancer. However, while breast cancer care today often provides state-of-the-art biomedical treatment, it can fail to address the broader psychosocial and quality-of-life issues associated with survivorship. Palliative care can potentially improve the quality of life and reduce the use of medical services in advanced breast cancer. Therefore, systematic approaches are crucial for breast cancer management.

This topic is centered around all aspects of the management of early and advanced breast cancer, including but not limited to early diagnosis, precise surgical method, prognostic biomarker, anti-HER2 therapy, hormone therapy, immune checkpoint therapy, nursing care, lymphedema management, rehabilitation, quality-of-life issue, and palliative care.

Yutian Zou, MD

Guest Editor


Breast Cancer; Surgery; Targeted Therapy; Nursing Care; Rehabilitation

Manuscript Submission Information

Manuscripts should be submitted online by submit system. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Original articles, case reports or comprehensive reviews are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website. Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. European Journal of Gynaecological Oncology is an international peer-reviewed open access journal published by MRE Press. Please visit the Instructions for Authors page before submitting a manuscript.The Article Processing Charge (APC) for publication in this open access journal is $1200. We normally offer a discount greater than 30% to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.

Share This Special Issue

Plan Papers (0 papers)

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time